Cochrane Abstracts
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Palivizumab for Preventing Severe Respiratory Syncytial Virus (RSV) Infection in Children." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433460/all/Palivizumab_for_preventing_severe_respiratory_syncytial_virus__RSV__infection_in_children.
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433460/all/Palivizumab_for_preventing_severe_respiratory_syncytial_virus__RSV__infection_in_children. Accessed January 12, 2025.
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433460/all/Palivizumab_for_preventing_severe_respiratory_syncytial_virus__RSV__infection_in_children
Palivizumab for Preventing Severe Respiratory Syncytial Virus (RSV) Infection in Children [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2025 January 12]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433460/all/Palivizumab_for_preventing_severe_respiratory_syncytial_virus__RSV__infection_in_children.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children
ID - 433460
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433460/all/Palivizumab_for_preventing_severe_respiratory_syncytial_virus__RSV__infection_in_children
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
